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ABSTRACT
QEEG Correlates of Cognitive Deficits in Multiple Sclerosis
During Targeted Cognitive Tasks
R. Brock Frost
Department of Psychology, BYU
Doctor of Philosophy
Multiple sclerosis (MS) is the most common neurological disorder of young adulthood
and is often associated with cognitive impairment and emotional dysfunction. Due to the nature
of the disease, the cognitive deficits in MS are often variable in their presentation, and consist of
deficits in processing speed, attention, working memory, and executive functioning. The
purpose of the present study was to explore common methods of documenting MS-related
cognitive deficits, to elucidate the relationship between the cognitive deficits seen in MS and
physiological markers of cognitive functioning (i.e., quantitative EEG), and to analyze the
relationship between cognitive deficits and mood dysfunction in MS. There were 26 participants
diagnosed with remitting-relapsing multiple sclerosis and 18 age, sex, and education matched
controls. Results of cognitive testing indicated deficits in gross cognitive functioning, language,
attention, processing speed, working memory, and executive functioning. A MANOVA
encompassing group, task (PASAT and SPT) and load (light and heavy) showed significant
group and load effects, but no main effect of task. The MS group performed worse than the
controls and both groups performed better on the light load than the heavy load. Post hoc
analysis indicated that performance on the PASAT 3 second trial was worse than on the PASAT
2 second trail compared to controls. Given that the PASAT 3 trial is theoretically easier than the
PASAT 2 trial and that the PASAT 3 was administered first, the above results likely reflect
learning effects. A Repeated Measures ANCOVA encompassing EEG and cognitive data
(PASAT and SPT) indicated group-level differences on task performance, and suggested that at
rest mean peak alpha frequency (PAF) is associated with performance on the PASAT, but not the
SPT. EEG coherence during cognitive tasks was reduced between short-range connections in the
theta, alpha, and beta frequency bins and enhanced in a limited number of long-range, anterior to
posterior connections in the theta frequency bin in the MS group compared to controls. Finally,
the MS participants had significantly more symptoms of depression and anxiety compared to
normal controls. A hierarchical multiple regression analysis suggested that cognitive functioning
is deleteriously affected by depression and anxiety. Overall, the results of this study substantiate
the feasibility of utilizing QEEG as a physiological indicator of cognitive and cortical
dysfunction in MS and show the importance of recognizing depression and anxiety and their
contributions to cognitive deficits in individuals with MS.
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QEEG Correlates of Cognitive Deficits in Multiple Sclerosis
During Targeted Cognitive Tasks
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system
in which myelin, the insulating sheath surrounding axons that facilitates the conduction of action
potentials, is the initial site of degeneration, with eventual expansion of the disease process to
include axonal dysfunction and destruction (Frohman et al., 2005). Multiple sclerosis was first
recognized as a distinct disease in the 1800’s and was initially considered to be fairly rare
(Talley, 2008). Presently, MS is the single most common neurological disease of young adults in
Western countries (Compston & Coles, 2002; Lassmann, 2008). Multiple sclerosis affects
approximately 30 per 100,000 people, ranging from a low of 0.3/100,000 in Africa to a high of
176/100,000 in Hungary (Organization, 2008). The estimated prevalence of MS in the United
States is 250,000 to 400,000 cases, with approximately 200 new cases diagnosed each week
(Anderson et al., 1992; Health, 2010; Kurtzke, 2000). Multiple sclerosis is a disease of young to
middle adulthood with a mean age of onset of 29.2 years. The prevalence of MS is higher in
females than in males with a ratio of approximately 3 to 1. Additionally, a diagnosis of MS is
associated with a modest decrease in life expectancy (Pryse-Phillips & Sloka, 2006; Sadovnick,
Ebers, Wilson, & Paty, 1992; Vukusic & Confavreux, 2001).
The disease course in MS is variable and several subtypes have been identified based on
disease presentation, which include: benign, relapsing-remitting, primary-progressive,
secondary-progressive, and relapsing-progressive (Lublin & Reingold, 1996). Disease
presentation of acute neuronal dysfunction is typically followed by periods of improvement or
relative stability (e.g. benign, relapse-remitting, and relapse-progressive), but may also present as
progressive deterioration of neuronal processes (e.g., primary/secondary-progressive), which
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results in heterogeneous symptoms across individuals with MS (Noseworthy, Lucchinetti,
Rodriguez, & Weinshenker, 2000). Regardless of the initial course of disease, the chronic
effects of repeated inflammation in the central nervous system (CNS) eventually lead to
functional decline in a significant portion of individuals with MS (Frohman et al., 2005).
The etiology of multiple sclerosis and the mechanisms of neuronal injury are unclear, but
likely include abnormal t-cell activation and proliferation, astrocytic blockage of remyelination,
increased influx of intracellular calcium resulting in neuronal injury, and retroviral-like infection
(Compston & Coles, 2002; Frohman et al., 2005; Keegan & Noseworthy, 2002; Noseworthy et
al., 2000). One well described mechanism of neuronal injury is the repetitive and continual
destruction of myelin (Lassmann, 2008), which is thought to be due to an autoimmune,
inflammatory response in which the immune system attacks the oligodendrocytes that form
myelin sheath in the CNS (Perry, 2008). After an inflammatory episode, remyelination of
neuronal processes typically occurs, however repeated inflammatory insults result in permanent
axonal damage and subsequent neuronal loss (Frohman et al., 2005; Gauthier et al., 2009). This
continual process of myelin insult and remyelization may account for the variable and
progressive pattern of symptoms and functional morbidity observed in relapsing-remitting MS
(Rao, Leo, Haughton, St. Aubin-Faubert, & Bernardin, 1989).
Genetic predisposition and environmental risk factors are also thought to play a role in
the development of MS (Ebers, Sadovnick, & Risch, 1995). Population based studies suggest
that MS susceptibility is likely linked to multiple genes and may be representative of genetic
equifinality (Sadovnick et al., 1993). Chemical exposure, stress, and vitamin deficiencies are
also thought to play a formative role in the development of MS (Marrie, 2004).
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Rating Scales
Historically, MS severity was measured by the degree of physical disability (Kurtzke,
1983). Consequently, the majority of the items on the most commonly used MS disability rating
system, the Expanded Disability Status Scale (EDSS), predominately assess physical dysfunction
(Kurtzke, 1983). The EDSS rates nine body systems (pyramidal, cerebellar, brain stem, sensory,
bowel and bladder, visual, cerebral-total, cerebral-mentation, and other), with scores ranging
from 0 (normal) to 6 (essential loss of function), with higher total scores indicating worse
function (Kurtzke, 1983). One reason that MS disability rating scales assess physical
dysfunction, rather than cognitive dysfunction, is largely due to the fact that physical complaints
are the most common presenting symptom of MS (Compston & Coles, 2002). Further, physical
disability is often not directly associated with intellectual or cognitive impairments, which are
difficult to accurately assess using rating scales (Satori & Edan, 2006; Sepulcre et al., 2006).
Two important limitations of the EDSS are its poor association with cognitive functioning and
the lack of an assessment of quality of life (Benedict et al., 2005; Foong et al., 1997; Ziemssen,
2009).
Studies indicate that 40 to 70 percent of individuals with MS have cognitive impairments
(Calabrese, 2006; Rao, Leo, Bernardin, & Unverzagt, 1991; Rao, Leo, Ellington, et al., 1991;
Rogers & Panegyres, 2007). As noted previously, physical symptoms have enjoyed a position of
primacy over cognitive symptoms when assessing and quantifying disease progression.
Cognitive function has not been used to assess disability associated with MS due to three related
issues: 1) physical symptoms are often the presenting complaint, 2) cognitive symptoms in MS
are typically heterogeneous and difficult to quantify using simple rating systems, and 3)
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cognitive symptoms often do not correlate with physical dysfunction (Benedict et al., 2006;
Foong et al., 1997; Rao, Leo, Bernardin, et al., 1991; Satori & Edan, 2006).
New MS disability rating systems are needed due in part to the historical dearth of
measures that attempt to quantify cognitive dysfunction, and the recent desire for short,
repeatable assessment tools for use in clinical trials (Cutter et al., 1999b; Rudick et al., 1997) In
response to this need, the Multiple Sclerosis Functional Composite (MSFC) was developed. The
MSFC is comprised of a gross motor task (25-foot walk), a fine motor task (9-hole peg board),
and a cognitive attention task (Paced Auditory Serial Addition Task; PASAT) (Fischer, Jak,
Knicker, Rudick, & Cutter, 2001). The MSFC can be used to track the fluctuating status of
disease processes, which allows for assessment of change over time (Fischer et al., 2001; Rudick
et al., 2009). Psychometric studies of the MSFC find good intra-rater (0.99) and inter-rater (1.0)
reliability, but significant practice effects are reported for both the 9-hole peg board and PASAT
subtests (Rosti-Otajarvi, Hamalainen, Koivisto, & Hokkanen, 2008). While the MSFC has some
limitations, it represents an emphasis shift from a primary focus on physical dysfunction to the
acknowledgment that cognitive deficits need to be assessed in individuals with MS.
Cognitive Function
Cognitive deficits in individuals with MS are heterogeneous within and between
diagnostic categories (e.g. relapse-remitting, progressive). Despite the variable presentation of
cognitive deficits, common cognitive impairments include: slowed mental processing speed,
impaired attention, executive dysfunction, and impaired memory (i.e., working memory, longterm storage and retrieval) (Calabrese, 2006; Kail, 1998; Thornton & DeFreitas, 2009).
Impairments in working memory are the most widely reported cognitive deficit in
individuals with MS, although the relationship between working memory deficits and impaired

5

attention and slow mental processing speed is unclear (Calabrese, 2006; Lengenfelder et al.,
2006). Slow mental processing speed and attention deficits in MS are common and affect
focused, sustained, and divided attention (Calabrese, 2006; De Sonneville et al., 2002; Demaree,
DeLuca, Gaudino, & Diamond, 1999; Forn, Belenguer, Parcet-Ibars, & Ávila, 2008). Frontal
lobe pathology is associated with executive dysfunction in MS, although global pathology
appears to play a prominent role as well (Foong et al., 1997). Neuropsychological measures of
phonemic and semantic fluency and measures of executive functioning appear to discriminate
healthy controls from MS participants (Henry & Beatty, 2006). As noted by Rao et al., (1991)
the above pattern of cognitive deficits resembles a subcortical dementia. A review of the
literature by Calabrese (2006) also found that the pattern of cognitive deficits in MS that effects
working memory, mental processing speed, attention, and executive functions is indicative of
subcortical dementia like pathology.
While many cognitive functions are impaired in MS, verbal intelligence, implicit memory
and visuo-spatial skills typically remain intact (Rao, Leo, Bernardin, et al., 1991). Further,
general intellectual function is also not typically affected by MS. The preservation of general
intellectual abilities is hypothesized to be due to: 1) cortical recruitment of additional cortical
regions to perform tasks that would normally be performed by fewer brain regions (Prakash, et
al., 2008) and 2) brain reorganization due to neuronal plasticity resulting in the appearance of
normal intellectual functioning despite underlying cortical lesions (Audoin et al., 2008; Mainero,
Pantano, Caramia, & Pozzilli, 2006; Prakash et al., 2008).
Psychological Functioning
Symptoms of depression are prevalent in MS (Minden & Schiffer, 1990) and may interact
with cognitive functioning in a “capacity-reducing” way. That is, depression in multiple
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sclerosis tends to degrade performance on tasks that demand increased attention, working
memory, and multi-step complex cognition (Arnett et al., 1999). Evidence to date suggests that
depressive symptoms are the result of increased cortical and subcortical dysfunction and may be
separable from major depression (Sadovnick et al., 1996). Additionally, psychological changes,
including depression, play a prominent role in the self-ratings of quality of life in the MS
population (Ziemssen, 2009), with individuals who endorse depressive symptoms reporting
reduced quality of life. As such, psychological functioning in general and depression in
particular are important factors to assess when evaluating the effects of MS on cognitive
function.
Magnetic Resonance Imaging (MRI)
Structural MRI studies provide a way to assess anatomical correlates of the cognitive
deficits observed in MS. Anatomical correlates include lesion location, extent and severity of
lesions (lesion burden), cortical and sub-cortical atrophy, and lesion progression over time
(Bermel & Bakshi, 2006; Lazeron et al., 2005; Lazeron, de Sonneville, Scheltens, Polman, &
Barkhof, 2006). In MS, lesions tend to be widespread including areas of the cortical mantle,
subcortical white matter, brainstem, cerebellum, and spinal cord (Ge, 2006). Brain atrophy
develops early on in the disease and represents generalized neuronal loss, which is only partially
moderated by discrete lesion load (Bermel & Bakshi, 2006; Filippi et al., 2003). Gross brain
atrophy is associated with cognitive impairment, while regional atrophy and lesion burden,
correlate modestly with specific neuropsychological impairments (Lazeron et al., 2005; Lazeron
et al., 2006; Rovaris et al., 2000). For example, Foong, et al. (2007) found that frontal lesion
load was associated with deficits in planning abilities. That is, increased frontal lesion load was
associated with a decrease in the ability to plan complex, sequenced actions. Similarly, Lazeron,
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et al. (2006) found that lesion load was associated with some measures of processing speed,
while total brain atrophy was associated with impaired attention and memory, and slow mental
processing speed.
Functional Magnetic Resonance Imaging (fMRI)
Functional magnetic resonance imaging (fMRI) in conjunction with measures of working
memory and attention/processing speed have also been used to elucidate the relationship between
neural pathology and cognitive deficits (Reddy et al., 2000; Staffen et al., 2002). A review of the
fMRI literature that assessed the neural correlates of working memory, attention, and processing
speed in MS, found increased activation in the prefrontal cortex, bilateral middle and superior
temporal cortex, left thalamus, basal ganglia, and left parietal lobe relative to controls during
sustained attention and speeded processing tasks (Mainero et al., 2006). Other studies have also
shown increased activation in the frontal and parietal lobes in MS populations during working
memory tasks (Staffen et al., 2002).
Interestingly, an fMRI study found that MS participants with cognitive impairments had
greater cortical activation on a working memory task compared to MS participants without
cognitive impairments and healthy controls, i.e. cognitive impairment separated individuals on
measures of brain activation not disease state (Chiaravalloti et al., 2005). Contrary to
expectations, the cognitively impaired MS group did not differ from the non-impaired MS group
on measures of lesion load, length of disease, or physical disability. In another study,
participants with MS showed greater cerebral activation in general and in the right prefrontal
cortex in particular during an attention task compared to controls (Prakash et al., 2008). In this
study, increased cerebral activation did not correlate with better task performance, suggesting
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increased cerebral activation may actually reflect the presence of cortical/subcortical deficits, and
hence cognitive dysfunction, rather than functional adaptation to underlying cortical dysfunction.
Functional MRI to date supports both the cortical recruitment and cortical reorganization
theories in MS (Mainero et al., 2006), but these theories are difficult to tease apart due to poor
temporal resolution, afferent/efferent ambiguity, and relatively poor spatial discrimination of
fMRI. Overall, fMRI findings suggest that cognitive deficits in attention and working memory
in MS are common, and provide some evidence for cortical recruitment/plasticity models in
individuals with MS (Chiaravalloti et al., 2005; Mainero et al., 2006; Prakash et al., 2008; and
Thornton & DeFreitas, 2009). However, increased cortical activation does not always result in
improved cognitive performance. Thus, cortical recruitment/plasticity may not be a functional
adaptation, but rather a significant indicator of cognitive dysfunction in MS.
Electroencephalogram (EEG)
The electroencephalogram (EEG) is a graphic representation of extra-cellular and cell
surface electrical gradients recorded by means of scalp electrodes (Binnie & Prior, 1994; Levitan
& Kaczmarek, 2002). It is a temporally sensitive measure of physiological processes. Positive
and negative field gradients between two points are represented by the falling and rising
waveforms that make up the EEG signal. The main components of the EEG are time/frequency
and waveform amplitude (Tyner, Knott, & Mayer, 1983). The EEG has classically been divided
into the frequency, or cycles per second, bins of: Delta (δ; 0-4hz), Theta (θ; 4-8hz), Alpha (α; 812hz), Beta (β; 12-30hz), and Gamma (γ; >30hz) (Buzsaki, 2006). Whereas the frequency bins
were created out of necessity for clear description and communication about the EEG, it is
recognized that there are individual differences in frequencies (Van Albada, Rennie, &
Robinson, 2007). Source localization techniques indicate that the frequency bins are discretely
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generated by specific cortical and subcortical structures and are sensitive to neuronal dysfunction
and death (Binnie & Prior, 1994; Michel, Lehmann, Henggeler, & Brandeis, 1992).
Quantitative Encephalogram (QEEG)
Quantitative encephalography (QEEG) is a method of analyzing EEG signals
algorithmically, rather than visually. QEEG allows for real time analysis of cortical activity
under a variety of conditions (Thatcher & Lubar, 2009). During QEEG, recordings are
simultaneously taken from many cortical regions, which can be compared to generate
information about regional differences in frequencies, region to region activity, activity
migration across regions, and the relative diffuseness of activity (Thatcher, Biver, & North,
2009). For QEEG to be an effective method of neurophysiological investigation four parameters
must be met; first, electrode application has to be uniformly named and consistently placed, e.g.,
10-20 system (Jurcak, Tsuzuki, & Dan, 2007), second, the EEG data must be relatively artifact
free, allowing for accurate analysis of signals of interest, third, the EEG must be recorded during
comparable conditions, and fourth, EEG features must be relatively stable within condition and
across time (Gudmundsson, Runarsson, Sigurdsson, Eiriksdottir, & Johnsen, 2007). These four
requirements determine the degree to which QEEG is an effective tool for measuring and
comparing cortical activity and is the underpinning of normative QEEG databases (Thatcher,
1998; Thatcher, Walker, Biver, North, & Curtin, 2003).
QEEG has been used to evaluate the relationship between cell groups (coherence), the
relative magnitude within frequency bands (peak frequency analysis; PFA), and the changes in
frequency characteristics during resting/tonic and active/phasic states (event related
desynchronization/synchronization; ERD/ERS) (Bazanova & Aftanas, 2008; Klimesch,
Doppelmayr, Schimke, & Ripper, 1997; Sauseng, Klimesch, Schabus, & Doppelmayr, 2005).
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Coherence is a measure of phase coupling or synchronization of EEG waveforms over
distance and time, is an indirect measure of functional/structural connectivity in the brain, and
can be expressed by the formula “Number of connections (N) x Strength of connections (S) in a
network” (Thatcher, 2010; Thatcher, Krause, & Hrybyk, 1986). As such, EEG coherence has
been used to identify cortical structures that are involved in discrete tasks, most prominently
memory, executive function, attention and processing speed tasks (Sauseng & Klimesch, 2008;
Sauseng et al., 2005). While, coherence has been associated with cognitive impairment and
lesion load (Kamel, S., & Hashem, 2004), the relationship between coherence and lesion load
appears to be moderated by cortical location and EEG frequency bin (Leocani et al., 2000).
Some studies question the use of coherence as a useful marker of functional connectivity,
primarily because the reliability of coherence is typically poor due to the use of average
referenced electrode montages (electrode maps) (Gudmundsson et al., 2007). Thatcher (2010)
notes the unreliability in coherence analysis is primarily due to the selection of an average
referent rather than a common or active referent, as an average referent produces phase shifting
towards the apex of the head in the EEG signal, and hence changes the morphology of the EEG.
This effectively diminishes any utility for coherence analysis from the get-go. An important
standardization of coherence studies would be to enact an active or common reference and
prohibit the use of an average reference, which would theoretically increase fidelity and
reliability.
Spectral analysis is the reduction of a frequency band (delta, theta, alpha, beta, gamma)
into its statistical components; i.e., into the frequency with the highest density for that band (peak
frequency) or into the statistical mean of the band (individual frequency), etc. (Angelakis, Lubar,
Stathopoulou, & Kounios, 2004). A significant portion of the spectral research has focused on
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peak alpha frequency analysis as a measure of cognitive function (Angelakis et al., 2004;
Klimesch, 2000). Research indicates that “faster” brains, that is, those that exhibit greater EEG
signal density higher in the discrete frequencies bins, typically perform better on discrete
cognitive tasks, particularly memory and attention tasks, including verbal and nonverbal
measures (Angelakis et al., 2004; Bazanova & Aftanas, 2008; Tzyy-Ping, Makeig, Stensmo, &
Sejnowski, 1997), however, the findings are mixed for general intellectual abilities (Doppelmayr,
Klimesch, Stadler, Pöllhuber, & Heine, 2002; Posthuma, Neale, Boomsma, & de Geus, 2001).
As such, peak alpha frequency has been described as a measure of cognitive preparedness rather
than a general measure of intellectual functioning (Angelakis et al., 2004).
Electroencephalographic activity can be split into two categories: tonic and phasic. Tonic
refers to the baseline or at rest EEG, while phasic refers to changes in the EEG due to task or
stimulus demands. Event related desynchronization (ERD) refers to changes in the EEG
between a tonic condition and a phasic condition and has been noted to affect frequency bins
(delta, theta, alpha, beta, gamma) differently (Klimesch, 1999). The discrete
electroencephalogram frequencies respond differentially to diverse cognitive tasks (Klimesch,
Doppelmayr, Russegger, Pachinger, & Schwaiger, 1998; Klimesch et al., 1997). The
relationship between tonic and phasic activity may be mediated by relative power of the tonic
frequency bands (Doppelmayr, Klimesch, Pachinger, & Ripper, 1998). Doppelmayr et al. (2002)
found tonic alpha power tone was associated with the extent of ERD during phasic EEG. While
most ERD research to date has focused on working memory tasks, which show a doubledissociation between lower theta and upper alpha on measures of task performance (Klimesch,
1999), preliminary results indicate that the lower alpha frequency range of 9.75 – 10.25hz
responds selectively to calculation tasks (Klimesch, 1999). Overall, the relationship of ERD to
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tonic EEG activity during calculation tasks has only recently been explored and is still in the
process of being elucidated.
Research in MS has begun to assess the relationship of cognitive and neuronal
functioning using QEEG. Historically, spectral analysis has been used to discriminate MS
participants from healthy controls on measures of peak alpha frequency, coherence, and general
slowing (Facchetti et al., 1994), but the relationship of QEEG findings and clinical significance
is unclear due to the relatively few studies that have assessed QEEG in MS populations. Recent
investigations find MS participants have slower reaction times during attention tasks which are
associated with increased activation of the high beta and gamma spectrum (Gonzalez-Rosa et al.,
2006; Vazquez-Marrufo et al., 2008). Within MS subgroups (benign, relapsing-remitting, etc.)
there are spectral differences in the high beta and gamma bins. Although, a study by VazquezMarrufo et al. (2008) failed to find tonic EEG differences within MS subgroups, this may have
been due to the relatively few cranial electrodes used (13), which only allowed the use of a
spectral density analysis rather than a peak frequency analysis, and/or the use of EEG segments
directly following stimulus presentation rather than throughout the task.
Purpose of Current Study
A weakness of current QEEG studies in MS populations is the lack of consistently used
testing procedures - such as uniform EEG configuration (number and placement), use of
standardized tests to assess cognitive domains of interest (memory, attention, executive
function), and limited use of neuropsychological tests to determine the extent and severity of
cognitive impairments. Few investigations into common themes in the body of QEEG research
such as spectral analysis, peak frequency analysis, and event related desynchronization has been
carried out in MS populations. The primary purpose of this study was to use a 24 EEG array to
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assess the relationship between QEEG features and cognitive performance (working memory,
attention/processing speed, and executive function) during EEG in MS participants who report
cognitive deficits.
Aims and Hypotheses
Aim 1: To assess the relationship between cognitive functioning and disability scores.
1a: MS participants’ scores on the RBANS (total and index scores), a measure of global
cognitive function, will be lower than matched control participants’ RBANS scores.
1b: The MSFC disability score will correlate with RBANS scores for both MS
participants and matched controls.
Aim 2: To assess the relationship between QEEG features and performance on cognitive
measures administered during EEG.
2a: Peak Alpha Frequency will discriminate between light and heavy cognitive loads on
the PASAT and SPT. Lower PAF will more accurately predict performance on heavy cognitive
load tasks than on light cognitive load tasks for both the MS and control groups.
2b: Multiple Sclerosis participants will show impairment on measures of coherence (the
degree to which diverse neuronal groups are coupled across space and time, and, as such, is an
indicator of functional connectivity in the brain) during the PASAT compared to normal
controls.
Aim 3: To assess QEEG and its relationship to cognitive performance.
3a. Spectral analysis will show regional QEEG differences between groups, that is the
MS participants will have frequency slowing in delta, theta, alpha, and beta frequencies
compared to matched controls.
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3b. MS participants with intact cognitive function, as measured by the RBANS overall
score, will have reduced QEEG frequency slowing compared to MS participants with cognitive
impairments.
Aim 4: To assess the relationship between psychological functioning (depression and anxiety)
and cognitive functioning.
4a: Psychological functioning will account for a unique portion of variance in cognitive
functioning, controlling for group membership, education, and PAF.
Methods
Participants
Participants included 26 individuals diagnosed with relapsing-remitting multiple sclerosis
and 18 age, sex, and education matched controls. The MS participants were recruited and
screened by a Board Certified Neurologist (Dr. John F. Foley, MD) from the Rocky Mountain
Neurological MS Clinic in Salt Lake City, Utah. Diagnosis of MS was made using the
McDonald criteria, an internationally used diagnostic criteria, which includes the identification
of at least two cortical or spinal lesions across time and space and one year of disease
progression, retrospective or prospective (McDonald et al., 2001; Polman et al., 2005). Study
inclusion criteria include diagnosis of relapsing-remitting MS, patient self-report of cognitive
impairments, and age 18 to 70 years. Study exclusion criteria included non-English-speaking,
use of sedative hypnotic agents within 72 hours of study, prominent visual deficits, dense
dominant limb paralysis, comorbid disorders with known cognitive impairment (e.g. traumatic
brain injury, stroke resulting in severe cognitive deficits, Parkinson’s disease, Huntington’s
disease, Alzheimer’s disease, severe dementia), and age < 18 years old or > 70 years.
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There were 18 control participants who were recruited from family members of the MS
participants as well as from the community by use of flyers, which were placed on
announcement boards at local grocery stores, university campuses, hospitals, and clinics.
Controls were matched to the MS participants for sex, age ± 3 years, and education ± 2 years.
The same inclusion and exclusionary criteria were used for MS participants and controls.
Procedures
The institutional review board at Brigham Young University approved the study protocol.
Written informed consent was obtained from participants prior to initiation of study procedures.
After obtaining informed consent, participants were scheduled for one 3 to 4 hour testing session.
The testing session consisted of cognitive testing, psychological questionnaires, and EEG
recording while performing cognitive tasks.
Demographic and medical history. Demographic and medical history was collected
using a questionnaire. Medical history included types and dates of medical diagnosis,
medication usage, traumatic injuries, and medical treatments.
Cognitive function. Standardized cognitive tests to assess general intellectual function,
attention, and executive function were administered. The Repeatable Battery for the Assessment
of Neuropsychological Status (McKay, Casey, Wertheimer, et al., 2007) assessed general
cognitive function. Processing speed, sustained attention and working memory were assessed
using the Paced Auditory Serial Addition Task (Gronwall, 1977), Digit Symbol Modalities Test
(Strauss, Sherman, & Spreen, 2006), and a Sternberg Paradigm Task (Smith, A., 1982).
Executive function was assessed using the Trail Making Test Parts A and B (Reitan & Wolfson,
1993), Controlled Oral Word Association Test (Gladsjo, Shuman, Miller, & Heaton, 1999), and
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the Wisconsin Card Sorting Test (Heaton, et al., 1993). Detailed test descriptions are provided
below.
A priori the presence of cognitive deficits are defined as scores on two or more
neuropsychological tests that were greater than 1 standard deviations (SD) below the normative
population mean. This definition of cognitive impairment in this study is similar to those used in
standard clinical neuropsychological evaluations (Binder, Iverson, & Brooks, 2009; Heaton,
Miller, Taylor, & Grant, 2004).
Global cognition. The Repeatable Battery for the Assessment of Neuropsychological
Status (RBANS) was designed as a screening tool for dementia, but has gained considerable
popularity as a screening instrument in a variety of disorders due to its short administration time,
co-normed index scores, availability of an easily interpreted summary score, and alternate forms
(McKay, Casey, Wertheimer, et al., 2007). The RBANS contains five domain-specific Index
Scores including Immediate Memory (List Learning and Story Memory subtests),
Visuospatial/Constructional (Figure Copy and Line Orientation subtests), Language (Picture
Naming and Semantic Fluency subtests), Attention (Digit Span and Coding subtests), and
Delayed Memory (List Recall, List Recognition, Story Recall, and Figure Recall subtests) as
well as provides a Total Scale Score. Index scores range from 40 to 160 with higher scores
indicating better performance. RBANS subtests correlate with individual neuropsychological
tests commonly used to examine similar domains (Aupperle, Beatty, DeNap Shelton, &
Gontkovsky, 2002; Beatty, 2004), and has good reliability and validity in MS populations
(Aupperle et al., 2002).
Processing speed, attention, and working memory. The Paced Auditory Serial Addition
Task (PASAT) measures sustained attention, rate of information processing, and to some degree
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simple mathematical calculation skill. Participants are required to add 59 pairs of randomized
digits without any aids. Each digit in the sequence is added to the prior digit. Fifty-nine pairs of
digits are added for each of two trials, (presenting rates: 3.0s or light load and 2.0s or heavy load
due to increased task difficulty) beginning with the 3.0s trial first and progressing to the 2.0s trial
(Gronwall, 1977). The PASAT is sensitive to attention, working memory and processing speed
in MS and correlates with MRI verified lesion loads (Rao, Leo, Bernardin, et al., 1991; Rao, St.
Aubin-Faubert, & Leo, 1989).
The Digit Symbol Modalities Test (DSMT) consists of 105 possible responses, which
entail converting numbers from 1 to 9 into random geometric designs during a 120 second
testing window (Strauss et al., 2006)Smith, A., 1982). The DSMT measures attention,
processing speed, spatial-construction, and non-verbal reasoning skills. The scores range from 0
to 105, with higher scores indicating better performance. The SDMT is sensitive to localized
and diffuse cerebral damage. Test-retest reliability is .80 for the paper-pencil version of the
SDMT (Smith, 1982).
The Sternberg Paradigm Task (SPT) consists of a light cognitive load (2 stimuli) and a
heavy cognitive load (4 stimuli) presentation. During the light cognitive load task the subject is
shown two random digits on a monitor and after a brief pause a third digit is presented. The
subject responds through a portable device yes if he/she believes that the third digit is the same
as one of the two proceeding digits and no if he/she does not. The heavy cognitive load
presentation is structurally similar to the light cognitive load except instead of two digits during
the stimulus presentation four digits are displayed. Again, during the response digit presentation
the subject indicates whether or not the response digit was present in the stimulus sequence
(Sternberg, 1969). Scores are represented in accuracy of response and range from 0 percent to
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100 percent with greater accuracy indicating better performance. The Sternberg paradigm is an
effective measure of information processing speed in general (Gontkovsky & Beatty, 2006) and
working memory in particular in MS (Drew, Starkey, & Isler, 2009; Rao, St. Aubin-Faubert, et
al., 1989).
Executive function. The Wisconsin Card Sorting Test (WCST) consists of four stimulus
cards and 128 response cards that depict figures of varying forms (crosses, circles, triangles, or
stars), colors (red, blue, yellow, or green), and numbers of figures (one, two, three, or four)
(Heaton, et al., 1993). During administration four stimulus cards are laid before the subject
while the subject is given 64 response cards. The subject is instructed to draw from the response
cards and place the drawn card with its matching stimulus card. The only feedback provided is
whether the “match” is incorrect or correct. After ten correct matches the rules are changed
without communication of the rule shift to the subject, which is repeated several times. Values
were generated for total categories completed, which is a gross measure of task performance and
consists of a score from 0 to 6, with higher scores indicating better performance; trials to
complete the first category, which is an indicator of the rapidity of a respondent’s adjustment to
the implicit rules of the task, with fewer trials indicating a better performance; perseverative
responses, which represents consistent responses that match an established sorting rule, with
lower scores generally indicating better performance; perseverative errors, which represent
responses that match a previous sorting rule and represent poor adjustment to explicit feedback,
with lower scores indicative of better performance; and failure to maintain set, which represents
a dropping of the sorting pattern after five, but before 10, correct trials, with lower scores
representing better performance. The WCST is sensitive to frontal lobe dysfunction. The
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WCST: Computerized Version-4 was used in order to ensure consistent test administration
across participants.
The Trail Making Test parts A and B are well-documented measures of visual scanning,
processing speed, and task switching a component of executive function (Lezak, 1995). The
Trail Making Test consists of two parts. In Part A, participants connect consecutively numbered
circles, while in Part B participants connect consecutively numbered and lettered circles that
alternate between the two sequences. Longer times to complete the tests are associated with
worse executive function. Psychometric studies indicate reliability coefficients above .80
(Spreen & Strauss, 1991), and several studies indicate that the two Trail Making tests are
sensitive to the global effects of brain injury (Botwinick, Storandt, Berg, & Boland, 1988;
Buchanan, Strauss, Kirkpatrick, Breier, & Carpenter, 1994).
The Controlled Oral Word Association test (COWA) requires that participants produce as
many words as possible that begin with the letters F, A, and S in one minute (Gladsjo et al.,
1999). The greater the number of words produced indicates better performance. Verbal fluency
is sensitive to focal cortical dysfunction in a variety of populations and are particularly useful in
identifying executive dysfunction (Henry & Crawford, 2004). Verbal fluency has moderate to
high correlations (.48 to .84) with verbal intelligence, which has been described as a “hold” test
for general intellectual functioning (Henry & Crawford, 2004) and test-retest reliability is high, r
= .70 (Tombaugh, Kozak, & Rees, 1999).
Psychological functioning. Psychological functioning appears to play a prominent role
in the self-ratings of quality of life, including cognitive deficits, in the MS population (Ziemssen,
2009). To assess depression and general anxiety, participants will complete the Hospital Anxiety
and Depression Scale (HADS) (Zigmond & Snaith, 1983). The HADS is a 14 item questionnaire
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that is the most widely used survey in medical participants (Herrmann, 1997), has separate
subscales for depression and anxiety, and is not heavily reliant on physical symptoms. Scores of
0 to 7 indicated normal, scores of 8 to 10 indicate borderline, and scores ≥11 on either the
depression or anxiety indices indicate symptoms of depression or anxiety. The HADS correlates
with psychiatric evaluations (Hayes et al., 2000; Zigmond & Snaith, 1983).
Physical dysfunction. The appropriate assessment of physical in participants with
multiple sclerosis has long been a concern (Kurtzke, 1983). As such, several rating scales have
been developed (Cutter et al., 1999a; Kurtzke, 1983). In order to assess physical dysfunction
participants completed the Multiple Sclerosis Functional Composite (MSFC) (Cutter et al.,
1999a). The MSFC consists of a twenty-five foot walk, a visual acuity exam, a 9-hole pegboard
test, and a version of the Paced Auditory Serial Addition Task. The MSFC score is a z-score
with a range of -1 to 1 with higher scores indicated better functioning. Psychometric studies of
the MSFC find good intra-rater (0.99) and inter-rater (1.0) reliability, but show significant
practice effects for both the 9-hole peg board and PASAT subtests (Rosti-Otajarvi et al., 2008).
Electroencephalogram (EEG). The EEG procedure consisted of 24 cranio-facial
transdermal electrodes placed according to the International 10-20 Electrode Placement System
(Jasper, 1958). Electrode sites were cleaned with a mildly-abrasive gel, approved for such
purposes, in order to establish and maintain the integrity of the EEG signal at acceptable
impedances (≤5kΩ). Recording of the EEG began with bio-calibrations including: eyes open,
eyes closed, look left, right, left, right, look up, down, up down, blink five times, smile and grit
teeth, and a period of relaxation. Each of these activities did not exceed 20 seconds. After biocalibrations participants completed approximately 5 minutes of an eyes closed, relaxed
condition. This was followed by cognitive testing, with each task followed by approximately 2-
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minutes of relaxed, eyes closed EEG recording. After the completion of the cognitive tasks, and
before the ending of the EEG recording, participants completed an approximately 5-minute eyes
open, relaxed condition.
Cognitive tasks during the EEG consisted of two trials of the Paced Auditory Serial
Addition Task (PASAT) (Tombaugh, 2006) and two trials of a Stenberg Paradigm Task (SPT)
(Sternberg, 1969). Presentation rates for the PASAT were 3.0s and then 2.0s; and for the STP
the heavy cognitive load trial was followed by the light cognitive load trial for all participants.
Quantitative EEG acquisition and processing. Electroencephalogram (EEG) data was
recorded from 20 scalp sites using industry standard EEG electrodes and the Cadwell Easy EEG
II (v. 2.1) 32-channel digital amplifier system (Kennewick, Washington). Two additional
electrode placements adjacent to the outer canthus of either eye enabled recording of vertical and
horizontal eye movements reflecting electro-occulographic (EOG) activity. Data from the EEG
was referenced to Cz and digitized continuously at 200Hz with a 12-bit analog-to-digital
converter. An electrode was placed on both ear lobes; serving the purposes as referents for
certain montages. Electrode impedance was maintained below 5k.
EEG was analyzed using NeuroGuide EEG Software (Applied Neuroscience, Inc.
Florida, USA). The QEEG software analyzed the EEG for artifact by use of statistical
algorithms, source amplitude and frequency, and allowed for temporally sensitive multi-subject
EEG comparison. Common artifact rejection included signals associated with ocular movement,
muscle tone, and EKG. Artifact rejection was visually reviewed for accuracy by a registered
polysomnographer (RPSGT).
Post EEG. After the removal of the EEG apparatus and scalp cleaning, participants
completed the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS),
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the Controlled Oral Word Association Test (COWAT), and the Wisconsin Card Sorting Test:
Computerized Version-4.
Statistical Analysis by Hypothesis
Descriptive statistics were conducted for demographic, medical, psychological, cognitive
data (i.e. general intellectual function, attention, and executive function), and physical function.
Continuous data are presented as means ± standard deviations (SD) and ranges, while categorical
variables are presented as proportions. Continuous data was analyzed by independent samples t
tests and categorical data by chi-square analysis; relationships between variables were analyzed
with correlations, ANOVA and its variants, and regressions. All statistical analyses were
conducted using IBM SPSS Statistics version 20.
Hypothesis 1: To assess the relationship between cognitive function and disability scores.
1a: MS participants’ scores on the RBANS (total and index scores), a measure of global
cognitive function, will be lower than matched control participants’ RBANS scores.
An independent samples t-test was used to measure group differences. X = group
membership (categorical variable); Y = RBANS total and domain scores (quantitative variable).
1b: The MSFC disability score will correlate with RBANS scores for both MS
participants and matched controls.
In order to assess the degree to which cognitive measures correlate with MSFC scores a
zero-order Pearson’s correlation will be calculated for RBANS scores (total and domain) and
MSFC total score for all participants.
Hypothesis 2: To assess the relationship between QEEG features and performance on cognitive
measures administered during EEG.
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2a: Peak Alpha Frequency will account for subject level differences in performance on
light and heavy cognitive loads on the PASAT and SPT.
In order to elucidate the relationship between group membership and task and load on
the PASAT and SPT, a repeated measures ANOVA using a group x task x load design was used.
A (2(group) × 2(task)) × 2(load) × 1(PAF) repeated measures analysis of covariance was used
in order to delineate main effects and interactions of group by task by load by PAF.
In order to compare the PASAT and SPT directly, scores on both measures were
converted to z-scores by taking the overall mean of the normal control group for the task and
trial and then subtracting this from the individual participants’ score for the same task and trial,
then dividing this score by the overall normal control standard deviation. Due to significant
overlap of signal in PAF across the head, a principle components analysis (PCA) of PAF at all
cranial electrode sites (F3, F4, F7, F8, C3, C4, T3, T4, P3, P4, T5, T6, O1, O2, Fz, Cz, and Pz)
was used to reduce the dimensionality of PAF across all electrode sites into a single signal. The
resulting extraction was used as the PAF covariate in the repeated measures ANCOVA.
2b: Multiple Sclerosis participants will show impairment on measures of coherence (the
degree to which diverse neuronal groups are coupled across space and time, and, as such, is an
indicator of functional connectivity in the brain) during the PASAT compared to normal
controls.
The normal control mean and standard deviation coherence values were used to create zscores for the MS group. These z-scores, which represent the deviation of the MS group EEG
coherence from the control population, were used to create coherence electrode maps.
Hypothesis 3: To assess spectral analysis and their relationship to cognitive performance.
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3a. Spectral analysis will show regional QEEG differences between groups, that is the
MS participants will have frequency slowing in delta, theta, alpha, and beta frequencies
compared to matched controls.
Initially, group means for each electrode site by frequency were computed.
Subsequently, mean differences between groups were computed by independent sample t tests for
each electrode site across delta, theta, alpha, and beta frequencies; α was adjusted to .01 to
control for multiple comparisons.
3b. MS participants with intact cognitive function, as measured by the RBANS overall
score, will have reduced QEEG frequency slowing compared to MS participants with cognitive
impairments.
The MS group was divided into two groups, a cognitive intact group and a cognitive
deficit group. The cognitive deficit group consisted of those participants with an RBANS total
scale score at or below the 16th percentile, which is equivalent to a ≤ -1.0 z-score. Subsequently,
peak frequency differences between the cognitive intact and deficit groups in the delta, theta,
alpha, and beta bins were computed with an independent t-test; α was adjusted to .01 to control
for multiple comparisons.
Hypothesis 4: To assess the relationship between psychological functioning (depression and
anxiety) and cognitive functioning.
4a: Psychological functioning will account for a unique portion of variance in cognitive
functioning, controlling for group membership, education, and PAF.
A two-step hierarchical multiple regression was performed with cognitive functioning as
the outcome, or dependent, variable. Cognitive functioning consisted of RBANS Total scores.
During the first step group membership (dummy coded), education, and PAF were entered into
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the regression. In the second step, psychological functioning was entered. Psychological
functioning consisted of HADS total scores.
Results
Descriptive Statistics
Descriptive statistics for demographic and medical data for the 26 individuals with
multiple sclerosis and 18 control participants are shown in Table 1. These was no difference for
age, t(42) = .425, p = .67, or education, t(42) = .11, p = .91 between the multiple sclerosis and
normal control groups. The ratio between males and females was 1:7.6 and 1:5 in the MS and
control groups, respectively; this difference was not significant, χ2 = .24, p = .63. All MS
participants were diagnosed with relapsing-remitting multiple scleroses and none were known to
be experiencing an active relapse. The average number of CNS activating medications in the MS
group was 5.46, with a mode of 4 and a range from 0 to 10; only three control participants were
taking CNS activating medications (Table 1). A significant difference between groups was noted
for medications, with the MS group taking a greater number of medications overall.
Descriptive statistics for all cognitive, psychological, and physical variables are presented
in Table 2. Participants with MS reported worse cognitive function on a self-report likert scale
compared to normal controls. Participants with MS reported more symptoms of anxiety and
depression and had worse physical function (MSFC, -0.04 vs. 0.79) than control participants.
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Table 1.
Descriptive Statistics for Demographic and Medical Variables by Group.
Multiple Sclerosis (n = 26)
Normal Control (n = 18)
Variable
M, SD (range)
M, SD (range)
Age (years)
49.2, 8.5 (33 – 66)
48.1, 9.0 (30 – 61)
Education (years)
15.2, 2.0 (11 – 20)
15.2, 1.8 (13 – 19)
Length of Disease (years)
9.1, 4.9 (0.5 – 19)
n/a
Sex (females)
Medications
MS Specific Medications
Avonex
baclofen
Copaxone
Detrol
Tysabri
Zanaflex
Other Psychoactive Medications
Anti-Depressants
Opioids
Atypical
Antipsychotics
Anxiolytics
Mood Stabilizers
Anti-Epileptics
Stimulants

n (%)
23 (88.5)

n (%)
15 (83.3)

t
0.42
0.11
n/a
χ2
0.24

4
4
1
1
10
5
25
11

2

3
4
2
6
7

1

Hypothesis 1: Cognitive Function and Disability Scores
1a: Individuals with MS had worse cognitive function on the RBANS Total Score,
Language Index, and Attention Index compared to controls. However, there were no differences
for Immediate Memory Index, Visual Construction Index, and Delayed Memory Index between
groups.
Similarly, the MS group exhibited slower mental processing speed (SDMT) and worse
executive function (Trails A and Trails B) compared to controls. On the two and three second
trials of the PASAT the MS group scored significantly lower than the control group indicating
deficits in attention, processing speed, working memory, and simple calculation skills. On the
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COWA the MS group generated significantly fewer words overall than the control group. Both
MS and controls groups completed a similar number of categories within a similar range of trials
on the WCST, but the MS group made significantly more perseverative responses and errors
compared to controls. On the SPT the MS participants were less accurate and had slower
response times than controls for both light and heavy cognitive loads.
Table 2.
Descriptive Statistics for Cognitive and Functional Measures
Multiple Sclerosis
Measure
(n = 26) M, SD
Self-Report of Cognitive Deficits
(Likert scale ranging from 1 (no
deficits) to 7 (significant deficits)
4.4, 0.8

Normal Control
(n = 18) M, SD

t

1.83, 1.2

8.57**

Hospital Anxiety & Depression Scale
Total score
Anxiety score
Depression score

19.8, 7.0
10.5, 4.3
9.3, 4.0

5.5, 3.0
3.9, 2.0
1.6, 1.7

8.07**
6.02**
7.69**

MS Functional Composite Score

-0.04, 0.6

0.79, 0.2

-5.84**

Repeatable Battery for the Assessment
of Neuropsychological Status
Total score
Immediate Memory score
Visual Construction score
Language score
Attention score
Delayed Memory score

91.3, 12.8
97.6, 15.4
92.1, 16.6
93.2, 15.4
88.9, 15.4
96.8, 12.0

103.8, 11.7
101.9, 14.9
100.4, 9.8
102.4, 9.8
106.2, 11.6
101.8, 13.9

-3.12**
-0.94
-1.90
-2.23*
-4.03**
-1.28

Digit Symbol Modalities Test
Total Correct

58.5, 16.0

81.0, 11.6

-5.07**

Trail Making Test Parts A & B
Trails A – Time (seconds)
Errors
Trails B – Time (seconds)
Errors

37.2, 14.2
0.1, 0.3
108.1 ± 71.9
0.6 ± 1.0

24.6, 5.3
0.3, 0.5
58.7, 13.1
0.3, 0.6

3.59**
-1.82
2.87*
0.94

Paced Auditory Serial Addition Task
Trial 3 Correct
Trial 2 Correct

40.4, 12.6
33.9, 13.2

54.6, 4.6
44.7, 8.0

-4.60**
-3.11**

Controlled Oral Word Association Test
F/A/S Total Correct
F/A/S Total Errors

32.3, 11.8
0.6, 1.0

41.9, 14.4
0.9, 0.9

-2.45*
-0.56
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F Correct
A Correct
S Correct
Wisconsin Card Sorting Task
Categories Completed
Trials to Complete 1st Category
Perseverative Responses
Perseverative Errors
Failure to Maintain Set

10.2, 4.1
9.8, 4.4
12.3, 4.8

13.9, 4.7
12.0, 6.1
16.0, 6.0

-2.83*
-1.41
-2.25*

5.3, 1.3
17.4, 12.9
16.42, 10.6
14.8, 9.0
1.42, 1.6

5.5, 1.5
20.3, 27.3
8.9, 6.5
8.5, 5.8
0.6, 0.9

-0.55
-0.48
2.69*
2.62*
1.96*

99 %, 0.02

-2.47*

711.1, 153.2
96 %, 0.03

3.52**
-2.22*

843.0, 163.5

3.67**

Sternberg Paradigm Task
Light Load Accuracy (percent)
95 %, 0.10
Light Load Response Time
(milliseconds)
1038.9, 372.9
Heavy Load Accuracy (percent)
91 %, 0.12
Heavy Load Response Time
(milliseconds)
1300.8, 509.8
Abbreviations are as follows: MS = multiple sclerosis
*p < .05, two-tailed. **p < .01, two-tailed. ***p <.001, two-tailed

1b: In order to test the relationship between the RBANS and the MSFC, zero-order
Pearson’s correlations were calculated for the MSFC and the RBANS Total and Index scores for
MS and control groups combined (Table 3). One MS subject was removed from the analyses
due to missing MSFC values. Significant positive correlations were found for the MSFC score
and the RBANS Total score, Visual Construction Index, Language Index, and Attention Index.
This finding suggests that increased functioning – as measured by the MSFC – is associated with
better cognitive functioning – as measured by the RBANS. In the MS group only analysis,
MSFC scores were positively correlated with RBANS Total score, Immediate Memory Index,
Attention Index, and Language Index, but not with the Visual Construction Index or the Delayed
Memory Index, which is similar to the combined groups analysis reported above. The MSFC did
not correlate significantly with the RBANS Total score or Index scores for the control group
(Table 3). Figure 1 shows a representative example of the correlations between MSFC scores
and RBANS scores, in this case MSFC scores with the RBANS Total scores.
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Table 3.
Zero-order correlations between the MSFC and RBANS scores
RBANS Global Scores
Total score
Immediate Memory
Visual Construction
Language
Attention
Delayed Memory
RBANS Global Scores
Total score
Immediate Memory
Visual Construction
Language
Attention
Delayed Memory

Multiple Sclerosis and Normal Control Combined (n = 43)
Pearson’s r
p
.592
<0.00
.279
0.07
.421
0.00
.495
0.00
.668
<0.00
.213
0.17
Multiple Sclerosis (n = 25)
Pearson’s r
p
.616
0.00
.415
0.04
.352
0.08
.468
0.02
.576
0.00
.207
0.32

Normal Control (n = 18)
Pearson’s r
p
-.227
0.36
-.383
0.12
.068
0.79
-.065
0.80
-.015
0.95
-.228
0.36

Figure 1. Correlations between MSFC and RBANS Total scores for MS and NC groups

Hypothesis 2: QEEG Features
2a: The normal control mean and standard deviation coherence values were used to create
z-scores for the PASAT 2 and 3 second trials and the SPT light and heavy trials. The MS
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group’s z-scores are as follows: PASAT 2 and 3 = -1.36 and -3.12, respectively; SPT Heavy and
Light = -1.71 and -1.51, respectively. A principle components analysis (PCA) of peak alpha
frequency (PAF) including all cranial electrode sites (F3, F4, F7, F8, C3, C4, T3, T4, P3, P4, T5,
T6, O1, O2, Fz, Cz, and Pz) was used to identify a single PAF component (For a description of
this technique see Fisher, Talathi, Cadotte, & Carney, 2009, p. 156). The PCA produced a
potential of 17 components, with the first accounting for approximately 82 percent of the
variance (eigenvalue = 13.93), with significant drop-off noted beyond the first potential
component. All electrode sites had extraction values for the main component above .73, with a
range from .73 to .92, which indicates that all electrode sites load on the extracted component, as
such, all subsequent analysis was restricted to a single component.
In order to elucidate the relationship between group membership and task and load a
Repeated Measures ANOVA was completed (Table 4). There was a main effect for group,
indicating significant differences between the groups on the PASAT and SPT. Review of the
testing data shows that the MS group scored significantly below the normal control group on all
measures (Table 2). There was a main effect for load but no main effect for task, showing
significant within-subjects effects. Post hoc pairwise analysis with both groups combined
indicates significant differences between PASAT 3 and 2 second trials (t(43) = -4.51, p = >.000)
and the PASAT 3and the SPT heavy load (t(43) = -2.57, p = >.01) but no significant differences
between the two loads on the SPT or between other contrasts between the two measures (i.e.,
light vs. heavy, heavy vs. heavy). Finally, there was a group x task interaction. Review of the
data suggests that the PASAT 3 second trial was particularly difficult for the MS group, which is
consistent with the above post hoc analysis. The group x task x load interaction was not
significant.
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Table 4.
Main effects and interactions for Group (MS, normal control), Task (PASAT, SPT), and Load (Light,
Heavy)
Main Effects
F
df
p
Partial Eta2
Between-Subjects Effects
Group
20.06
1
<0.00
0.32
Within-Subjects Effects
Task
0.91
1
0.35
0.02
Load
5.30
1
0.03
0.11
Interactions
Group x Task
Group x Load
Group x Task x Load
Task x Load

F
0.91
5.31
2.48
2.47

df
1
1
1
1

p
0.35
0.03
0.12
0.12

Partial Eta2
0.02
0.11
0.06
0.06

In order to test the hypothesis that Peak Alpha Frequency will account for group level
differences in performance on light and heavy cognitive loads on the PASAT and SPT a
Repeated Measures ANCOVA with group as the between-participants variable, the two
conditions of the PASAT and SPT (within-participants task and load), and the PAF component
score as a covariate was carried out. Results are shown in Table 5. The assumption of sphericity
was not violated (Mauchly’s W = 1.0 and Greenhouse-Geisser = 1.0), indicating homogeneity of
variance in the dependent variables and signaling that the data is appropriate for analysis with a
repeated measures ANCOVA. There was a main effect for group, indicating significant
differences between the groups on the PASAT and SPT. Additionally, there continued to be a
main effect for task. Similarly, the group x task interaction continued to be significant. There
was a significant between-subjects effect for PAF, indicating that PAF was related to
performance on the PASAT or SPT, or both. Post hoc analysis utilizing pairwise comparison of
mean score differences indicates significant differences for load (mean difference = -.50, p =
.02), but not for task (mean difference = -.32, p = .32). Comparison of marginal means shows,
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similar to the MANOVA reported on above, that the PASAT 3 trial was largely responsible for
the significant results (Table 6). To further analyze the relationship between PAF and the
PASAT and SPT, partial correlations, controlling for group membership, for PAF and PASAT
were as follows, PASAT 3 (r = .44, p < .00), PASAT 2 (r = .33, p = .03). Partial correlations,
controlling for group membership, for PAF and SPT were as follows, SPT Light (r = .12, p =
.46), and SPT Heavy (r = .088, p = .58). These results suggest that the effect of PAF was largely
due to the relationship between PAF and both trials of the PASAT, whereas the SPT does not
appear to be associated with variations in PAF. Overall, these results suggest that there are
significant group level differences in cognitive performance on the PASAT and SPT, and that
variations in PAF are associated with performance on the PASAT, but not on the SPT.
Table 5.
Main effects and interactions for Group (MS, normal control), Task (PASAT, SPT), and Load (Light,
Heavy), with PAF as a covariate
Main Effects
F
df
p
Partial Eta2
Between-Subjects Effects
Group
19.36
1
<0.00
0.32
PAF Component Score
5.36
1
0.03
0.12
Within-Subjects Effects
Task
1.00
1
0.32
0.02
Load
5.54
1
0.02
0.12
Interactions
Group x Task
Group x Load
Group x Task x Load
Task x Load
Task x PAF
Load x PAF
Task x Load x PAF

F
0.61
4.61
2.12
2.52

df
1
1
1
1

p
0.44
0.04
0.15
0.12

2.32
1.85
0.77

1
1
1

0.14
0.18
0.38

Partial Eta2
0.02
0.10
0.05
0.06
0.05
0.04
0.02

33

Table 6.
Comparison of marginal means for Group (MS, normal control), Task (PASAT, SPT), and Load (Light,
Heavy), with PAF as a covariate
95% Confidence Interval
Group
Task
Load
Mean
Std. Error
Lower Bound
Upper Bound
Multiple
PASAT
Light
-3.02
.395
-3.81
-2.23
Sclerosis
Heavy
-1.31
.268
-1.85
-0.80
SPT
Light
-1.69
.447
-2.59
-0.80
Heavy
-1.50
.439
-2.38
-0.60
Normal
PASAT
Light
-0.14
.475
-1.10
0.82
Control
Heavy
-0.10
.322
-0.72
0.60
SPT
Light
-0.04
.538
-1.23
1.05
Heavy
-0.03
.529
-1.10
1.04

2b. In order to identify possible difference in functional neuronal connectivity between
groups, comparison of MS and NC coherence during cognitive tasks was completed. Coherence
in the theta, alpha, and beta bands during both trials of the PASAT generally showed reduced
coherence for both intra- and inter-hemispheric electrode pairs that were comprised of shorter
distance connections. Increased coherence was noted on the PASAT2 and PASAT3 in the theta
band for a limited number of electrodes. In summary, while the overall trend was for reduced
coherence in the MS group compared to normal controls (see Figures 2, 3, 4, 5, 6, 7), there was
increased coherence between a few electrode pairs that were separated by longer distances (see
Figures 2 and 5).
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Figure 2. Comparison of MS and normal controls EEG coherence during the PASAT2 in the theta band. Coherence values have
been z-transformed and color-coded to aid in interpretation; scores of -1 to <-3 (blue colors) indicate reduced levels of coherence
between electrode pairs in the MS group compared to normal controls, while scores of 1 to >3 (red colors) indicate increased
coherence. Reduced coherence is noted between frontal and temporal electrodes. Both intra- and inter-hemispheric reductions are
noted. Inter-hemispheric increases in coherence between parietal and frontal electrode sites are also present.
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Figure 3. Comparison of MS and normal controls EEG coherence during the PASAT2 in the alpha band. Coherence values have
been z-transformed and color-coded to aid in interpretation; scores of -1 to <-3 (blue colors) indicate reduced levels of coherence
between electrode pairs in the MS group compared to normal controls, while scores of 1 to >3 (red colors) indicate increased
coherence. Reduced coherence is noted between frontal and temporal electrodes. Both intra- and inter-hemispheric reductions are
noted.
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Figure 4. Comparison of MS and normal controls EEG coherence during the PASAT2 in the beta band. Coherence values have
been z-transformed and color-coded to aid in interpretation; scores of -1 to <-3 (blue colors) indicate reduced levels of coherence
between electrode pairs in the MS group compared to normal controls, while scores of 1 to >3 (red colors) indicate increased
coherence. Reduced coherence is noted between frontal and temporal electrodes. Both intra- and inter-hemispheric reductions are
noted.
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Figure 5. Comparison of MS and normal controls EEG coherence during the PASAT3 in the theta band. Coherence values have
been z-transformed and color-coded to aid in interpretation; scores of -1 to <-3 (blue colors) indicate reduced levels of coherence
between electrode pairs in the MS group compared to normal controls, while scores of 1 to >3 (red colors) indicate increased
coherence. Reduced coherence is noted between frontal and temporal electrodes. Both intra- and inter-hemispheric reductions are
noted. Inter-hemispheric increases in coherence between parietal and frontal/temporal electrode sites are also present.
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Figure 6. Comparison of MS and normal controls EEG coherence during the PASAT3 in the alpha band. Coherence values have
been z-transformed and color-coded to aid in interpretation; scores of -1 to <-3 (blue colors) indicate reduced levels of coherence
between electrode pairs in the MS group compared to normal controls, while scores of 1 to >3 (red colors) indicate increased
coherence. Reduced coherence is noted between frontal and temporal electrodes. Both intra- and inter-hemispheric reductions are
noted.
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Figure 7. Comparison of MS and normal controls EEG coherence during the PASAT3 in the beta band. Coherence values have
been z-transformed and color-coded to aid in interpretation; scores of -1 to <-3 (blue colors) indicate reduced levels of coherence
between electrode pairs in the MS group compared to normal controls, while scores of 1 to >3 (red colors) indicate increased
coherence. Reduced coherence is noted between frontal and temporal electrodes. Both intra- and inter-hemispheric reductions are
noted.
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Hypothesis 3: Spectral Analysis
3a. In order to identify possible group difference in QEEG features spectral analysis was
carried out for both the MS and normal control group in the delta, theta, alpha, and beta EEG
frequency bins. Independent samples t tests, with α adjusted to .01 to control for multiple
analysis, were computed in order to compare potential differences between the MS and normal
control groups in peak frequency. There were no significant differences in mean peak frequency
between groups for delta, theta, alpha, or beta frequency bins. Means, standard deviations, and
statistical analysis are presented in Table 7 (Delta), Table 8 (Theta), Table 9 (Alpha), and Table
10 (Beta).
Table 7.
Comparison of Mean Peak Frequency in the Delta Band by Electrode Site by Group
Multiple Sclerosis (n = 26)
Normal Control (n = 18)
Electrode
Mean ± SD
Mean, SD
F3
2.09, 0.12
2.13, 0.10
F4
2.10, 0.10
2.13, 0.10
C3
2.18, 0.10
2.19, 0.09
C4
2.15, 0.11
2.19, 0.06
P3
2.18, 0.09
2.19, 0.06
P4
2.16, 0.11
2.18, 0.05
O1
2.20, 0.10
2.15, 0.12
O2
2.19, 0.11
2.16, 0.10
F7
2.00, 0.17
2.03, 0.07
F8
2.01, 0.14
2.05, 0.13
T3
2.11, 0.13
2.14, 0.10
T4
2.10, 0.12
2.13, 0.13
T5
2.17, 0.14
2.16, 0.11
T6
2.16, 0.15
2.16, 0.10
Fz
2.15, 0.10
2.17, 0.10
Cz
2.20, 0.09
2.21, 0.08
Pz
2.18, 0.08
2.19, 0.07
Mean
2.14, 0.06
2.15, 0.05

t(42)
-1.07
-0.93
-0.59
-1.48
-0.35
-0.80
1.63
0.82
-0.55
-0.80
-1.00
-0.57
0.24
0.11
-0.37
-0.33
-0.46
n/a

p
0.29
0.36
0.56
0.15
0.73
0.43
0.11
0.42
0.59
0.43
0.33
0.57
0.81
0.91
0.71
0.74
0.65
n/a
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Table 8.
Comparison of Mean Peak Frequency in the Theta Band by Electrode Site by Group
Multiple Sclerosis (n = 26)
Normal Control (n = 18)
Electrode
Mean, SD
Mean, SD
F3
5.80, 0.25
5.84, 0.23
F4
5.80, 0.27
5.85, 0.22
C3
5.85, 0.29
5.81, 0.22
C4
5.85, 0.29
5.83, 0.21
P3
5.88, 0.33
5.77, 0.26
P4
5.88, 0.30
5.83, 0.22
O1
5.84, 0.31
5.84, 0.18
O2
5.86, 0.30
5.89, 0.18
F7
5.75, 0.26
5.75, 0.29
F8
5.78, 0.24
5.76, 0.27
T3
5.77, 0.30
5.71, 0.27
T4
5.84, 0.27
5.75, 0.28
T5
5.89, 0.34
5.82, 0.06
T6
5.93, 0.30
5.89, 0.24
Fz
5.80, 0.28
5.84, 0.21
Cz
5.84, 0.31
5.79, 0.20
Pz
5.90, 0.33
5.84, 0.18
Mean
5.84, 0.05
5.81, 0.05

t(42)
-0.49
-0.66
0.44
0.22
1.22
0.62
-0.02
-0.32
-0.01
0.25
0.69
1.05
0.75
0.56
-0.46
0.55
0.68
n/a

p
0.63
0.52
0.66
0.82
0.23
0.54
0.99
0.76
0.99
0.80
0.49
0.30
0.46
0.58
0.65
0.59
0.50
n/a

Table 9.
Comparison of Mean Peak Frequency in the Alpha Band by Electrode Site by Group
Multiple Sclerosis (n = 26)
Normal Control (n = 18)
Electrode
Mean, SD
Mean, SD
t(42)
F3
9.48, 0.30
9.48, 0.28
-0.26
F4
9.50, 0.30
9.52, 0.27
-0.27
C3
9.54, 0.32
9.56, 0.27
-0.25
C4
9.59, 0.37
9.63, 0.26
-0.44
P3
9.65, 0.39
9.71, 0.33
-0.61
P4
9.66, 0.41
9.73, 0.30
-0.56
O1
9.68, 0.42
9.77, 0.36
-0.75
O2
9.68, 0.43
9.78, 0.38
-0.75
F7
9.46, 0.27
9.54, 0.27
-0.93
F8
9.47, 0.26
9.58, 0.28
-1.30
T3
9.54, 0.30
9.68, 0.27
-1.55
T4
9.57, 0.33
9.69, 0.29
-1.24
T5
9.58, 0.40
9.68, 0.28
-0.87
T6
9.62, 0.43
9.73, 0.34
-0.95
Fz
9.44, 0.31
9.47, 0.27
-0.33
Cz
9.50, 0.37
9.55, 0.27
-0.48
Pz
9.63, 0.45
9.72, 0.32
-0.73
Mean
9.56, 0.08
9.64, 0.10
n/a

p
0.98
0.79
0.81
0.66
0.55
0.58
0.46
0.46
0.36
0.20
0.13
0.22
0.39
0.35
0.74
0.64
0.47
n/a
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Table 10.
Comparison of Mean Peak Frequency in the Beta Band by Electrode Site by Group
Multiple Sclerosis (n = 26)
Normal Control (n = 18)
Electrode
Mean, SD
Mean, SD
t(42)
F3
16.98, 0.96
16.86, 0.42
0.50
F4
17.01, 1.07
16.91, 0.49
0.38
C3
16.72, 0.89
16.82, 0.45
-0.43
C4
16.83, 1.07
16.66, 0.66
0.61
P3
16.15, 0.94
16.35, 0.71
-0.77
P4
16.24, 1.01
16.40, 0.75
-0.56
O1
16.24, 1.05
16.19, 0.87
0.16
O2
16.26, 1.08
16.32, 0.97
-0.18
F7
17.02, 0.78
16.94, 0.55
0.37
F8
16.87, 0.73
16.80, 0.53
0.37
T3
17.10, 1.14
16.82, 0.81
0.91
T4
17.27, 1.24
16.85, 0.73
1.27
T5
16.44, 1.02
16.37, 0.74
0.27
T6
16.40, 1.01
16.47, 0.97
-0.21
Fz
16.65, 0.85
16.61, 0.36
0.21
Cz
16.57, 0.87
16.63, 0.52
-0.27
Pz
16.04, 1.01
16.30, 0.75
-0.94
Mean
16.63, 0.37
16.61, 0.24
n/a

p
0.62
0.71
0.67
0.55
0.44
0.58
0.87
-0.86
0.71
0.72
0.37
0.21
0.79
0.84
0.83
0.79
0.35
n/a

3b. The MS cognitively intact group was compared to the cognitive deficit group.
Demographic data for the two groups is presented in Table 11. There were no statistically
significant differences for any demographic variable between groups.
Table 11.
Demographic Data for the Cognitive Deficit and Cognitive Intact Groups
Cognitive Deficit
Cognitive Intact
(≤ -1.0 z-score) (n = 9)
(> -1.0 z-score) (n = 17)
Variable
Mean, SD
Mean, SD
Age (years)
45.0, 9.7
51.4, 7.2
Education (years)
14.7, 2.4
15.6, 1.8
LoD (years)
9.9, 5.7
8.7, 4.5
LoD = length of disease

t
-1.92
-1.25
0.60

p
0.07
0.22
0.56

Spectral analysis of mean peak frequency was carried out for the MS cognitive intact and
cognitive deficit group for the delta, theta, alpha, and beta EEG frequency bins using
independent samples t tests, with α adjusted to .01 to control for multiple analysis. There were
no significant differences in mean peak frequency between the groups for delta, theta, alpha, or
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beta frequency bins. Means, standard deviations, and statistical analysis are presented in Table
12 (Delta), Table 13 (Theta), Table 14 (Alpha), and Table 15 (Beta).
Table 12.
Comparison of Mean Peak Frequency in the Delta Band by Electrode Site by Group
Cognitive Deficit
Cognitive Intact
(≤ -1.0 z-score) (n = 9)
(> -1.0 z-score) (n = 17)
Electrode Site
Mean, SD
Mean, SD
t
F3
2.07, 0.13
2.10, 0.13
-0.54
F4
2.09, 0.06
2.11, 0.11
-0.40
C3
2.16, 0.10
2.18, 0.10
-0.49
C4
2.14, 0.11
2.15, 0.10
-0.26
P3
2.16, 0.07
2.19, 0.10
-0.84
P4
2.14, 0.14
2.17, 0.09
-0.57
O1
2.19, 0.13
2.21, 0.08
-0.34
O2
2.20, 0.11
2.19, 0.11
0.28
F7
1.95, 0.18
2.04, 0.16
-1.35
F8
1.98, 0.15
2.03, 0.14
-0.87
T3
2.04, 0.16
2.14, 0.10
-2.03
T4
2.07, 0.13
2.12, 0.12
-0.90
T5
2.15, 0.14
2.18, 0.13
-0.65
T6
2.16, 0.19
2.16, 0.13
-0.11
Fz
2.15, 0.11
2.15, 0.10
0.01
Cz
2.21, 0.12
2.20, 0.08
0.34
Pz
2.19, 0.07
2.17, 0.09
0.50
Mean
2.12, 0.07
2.15, 0.05
n/a

p
0.59
0.69
0.63
0.79
0.41
0.57
0.73
0.79
0.19
0.40
0.05
0.38
0.52
0.92
0.99
0.74
0.62
n/a

Table 13.
Comparison of Mean Peak Frequency in the Theta Band by Electrode Site by Group
Cognitive Deficit
Cognitive Intact
(≤ -1.0 z-score) (n = 9)
(> -1.0 z-score) (n = 17)
Electrode Site
Mean, SD
Mean, SD
t
F3
5.89, 0.08
5.75, 0.06
1.29
F4
5.87, 0.31
5.77, 0.25
0.87
C3
5.96, 0.27
5.79, 0.29
1.50
C4
5.93, 0.34
5.81, 0.27
0.97
P3
5.97, 0.35
5.84, 0.32
0.96
P4
5.96, 0.35
5.84, 0.27
0.98
O1
5.94, 0.36
5.79, 0.28
1.21
O2
5.94, 0.34
5.82, 0.28
0.94
F7
5.84, 0.26
5.70, 0.25
1.36
F8
5.86, 0.27
5.74, 0.23
1.22
T3
5.83, 0.34
5.74, 0.29
0.73
T4
5.89, 0.33
5.81, 0.25
0.68
T5
5.97, 0.40
5.85, 0.30
0.92
T6
6.02, 0.42
5.89, 0.21
1.07
Fz
5.86, 0.32
5.77, 0.25
0.79
Cz
5.93, 0.35
5.79, 0.28
1.18
Pz
6.01, 0.38
5.84, 0.30
1.22
Mean
5.92, 0.06
5.80, 0.05
n/a

p
0.21
0.39
0.15
0.34
0.34
0.34
0.24
0.36
0.19
0.23
0.47
0.51
0.37
0.29
0.43
0.25
0.23
n/a
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Table 14.
Comparison of Mean Peak Frequency in the Alpha Band by Electrode Site by Group
Cognitive Deficit
Cognitive Intact
(≤ -1.0 z-score) (n = 9)
(> -1.0 z-score) (n = 17)
Electrode Site
Mean, SD
Mean, SD
F3
9.36, 0.35
9.55, 0.26
F4
9.38, 0.33
9.56, 0.27
C3
9.46, 0.36
9.58, 0.30
C4
9.41, 0.40
9.68, 0.33
P3
9.51, 0.44
9.72, 0.35
P4
9.47, 0.47
9.76, 0.36
O1
9.52, 0.48
9.77, 0.37
O2
9.48, 0.48
9.79, 0.37
F7
9.39, 0.39
9.50, 0.19
F8
9.39, 0.30
9.51, 0.22
T3
9.53, 0.38
9.55, 0.26
T4
9.49, 0.42
9.62, 0.28
T5
9.48, 0.44
9.64, 0.37
T6
9.42, 0.49
9.72, 0.37
Fz
9.31, 0.35
9.51, 0.28
Cz
9.33, 0.39
9.59, 0.34
Pz
9.42, 0.48
9.74, 0.41
Mean
9.43, 0.06
9.63, 0.10

t
-1.56
-1.46
-0.92
-1.80
-1.31
-1.80
-1.47
-1.88
-0.96
-1.13
-0.19
-0.92
-0.93
-1.80
-1.62
-1.75
-1.78
n/a

p
0.13
0.16
0.36
0.08
0.20
0.09
0.16
0.07
0.35
0.27
0.85
0.36
0.36
0.08
0.12
0.09
0.09
n/a

Table 15.
Comparison of Mean Peak Frequency in the Beta Band by Electrode Site by Group
Cognitive Deficit
Cognitive Intact
(≤ -1.0 z-score) (n = 9)
(> -1.0 z-score) (n = 17)
Electrode Site
Mean, SD
Mean, SD
F3
17.26, 0.81
16.84, 1.02
F4
17.36, 0.87
16.82, 1.15
C3
16.82, 0.59
16.67, 1.03
C4
17.05, 0.74
16.72, 1.22
P3
16.06, 0.56
16.20, 1.10
P4
16.17, 0.42
16.28, 1.23
O1
16.21, 0.79
16.26, 1.20
O2
16.17, 0.84
16.31, 1.21
F7
17.25, 0.80
16.90, 0.77
F8
16.97, 0.46
16.82, 0.85
T3
17.25, 1.25
17.02, 1.12
T4
17.25, 1.04
17.27, 1.37
T5
16.58, 0.84
16.37, 1.11
T6
16.32, 0.69
16.45, 1.16
Fz
16.89, 0.49
16.53, 0.98
Cz
17.01, 0.67
16.35, 0.89
Pz
15.87, 0.37
16.13, 1.22
Mean
16.73, 0.49
16.58, 0.32

t
1.07
1.21
0.38
0.73
-0.35
-0.26
-0.13
-0.30
1.09
0.47
0.48
-0.05
0.50
-0.32
1.04
1.95
-0.63
n/a

p
0.30
0.24
0.71
0.47
0.73
0.80
0.90
0.77
0.29
0.64
0.63
0.96
0.62
0.76
0.31
0.06
0.54
n/a
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Hypothesis 4: Psychological Functioning
A multiple regression was used to explore the relationship between cognitive functioning
and psychological functioning. Overall cognitive function (RBANS Total score) was predicted
by Group (coded 0 = Multiple Sclerosis, 1 = Normal Control), Education, Peak Alpha Frequency
(PAF), and Psychological Functioning (PF) (i.e., HADS total score). The total sample size was
44; no data points were missing.
Table 16.
Results of a Two-Step Hierarchical Regression to Predict Cognitive Functioning from Group, Education
(ED), and PAF, and Psychological Functioning (PF)
RBANS
Group
ED
PAF
PF
b
β
Group
-0.43
-3.90
-0.14
ED
0.15
0.02
0.45
0.06
PAF
0.40
-0.12
0.14
4.89
0.36
PF
-0.45
0.78
-0.11
-0.04
-0.48
-0.32
Intercept = 98.32
Mean
SD

96.16
13.60

_____a
_____a

15.2
1.9

_____b
_____b

13.93
9.10

R2 = 0.358
R2adj = 0.293
R = 0.599***
Note: Group, ED, and PAF were added in step one; PF was added in step-two. *p < .05, two-tailed. **p <
.01, two-tailed. ***p <.001, two-tailed. Table adapted from (Warner, 2008, p. 582).
a. Group was a dummy coded variable (Multiple Sclerosis = 0, Normal Control = 1). As such means and
standard deviations are note reported. The sample included 26 MS participants and 18 Normal Controls.
b. PAF is the product of a transformation (i.e., reduction of dimensionality), which decouples PAF from
its original metric (i.e., 8 to 12hz) and results in a mean of 0 and a standard deviation of 1.

A two-step hierarchical multiple regression was performed with cognitive functioning as
the dependent variable. During the first step group membership, education, and PAF were
entered into the regression. In the second step psychological functioning was added to the model
(see Table 16). The overall regression in step-one, which included group membership,
education, and PAF, was significant, R = 0.57, R2 = 0.32, R2adj = 0.27, F(4, 39) = 6.30, p = <.00.
The addition of psychological functioning to the model was significant, and resulted in a slight

46

increase in predictive power for the overall regression model, R = 0.60, R2 = 0.36, R2adj = 0.30,
F(4, 39) = 5.45, p = <.00.
Discussion
Cognitive Function
The current study explored the complex relationship between cognitive deficits, QEEG
features, and cognitive performance during EEG in MS participants. The MS participants
exhibited significant cognitive impairments compared to matched controls. For instance, the
RBANS global cognition score was significantly reduced in the MS group compared to controls
(91±13 vs. 103±12; standard score). Specifically, differences in cognitive functioning were
found in language and attention; while immediate and delayed memory and visuo-constructional
abilities did not differ between the groups. It should be noted that while global cognitive
functioning in the MS group was significantly lower than controls, the MS groups’ mean scores
fell within the low average range of normal cognitive function.
Previous research has identified memory deficits as part of the hallmark pattern of
cognitive decline in MS (Rao, Leo, Bernardin, et al., 1991). As noted above, there were no
differences between our MS and control group on immediate or delayed memory indices. One
study that utilized the RBANS found deficits in the immediate and delayed memory indices in
individuals with MS who had a MMSE score of < 27 (impaired cognitive function), while
individuals with a MMSE score ≥ 27 (normal cognitive function) had RBANS memory scores
that were not impaired (Beatty, 2004). Our findings are similar to those of Beatty et al. (2004) in
that our MS group had both relatively normal global cognitive function and preserved memory
functions (encoding, storage, and retrieval), which are sub-served by medial temporal lobe
structures. In contrast, on a Sternberg Paradigm Test our MS group exhibited significant
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impairments on accuracy and speed of response compared to controls, suggesting that our MS
participants had impaired working memory, a function of the frontal lobes (Prabhakaran,
Narayanan, Zhao, & Gabrieli, 2000). The intact immediate and delayed memory but impaired
working memory suggests that brain regions may be differentially affected and lesion location is
likely critical in determining the type and severity of cognitive impairments in individuals with
MS. Deficits in visuo-spatial function in our MS participants approached significance (p = 0.07).
This finding is interesting in that visuo-spatial deficits are uncommon in MS populations
(Calabrese, 2006). Given our relatively modest sample size, it may be that a larger sample
would have found visuo-spatial impairments in our MS participants compared to controls.
Another possible explanation for these findings may be limitations in the RBANS complex
figure scoring. An analysis by Duff et al. (2007) of the RBANS’ complex figure scoring
suggests that the published scoring criteria may over-estimate the severity of visuo-spatial
impairments, particularly in populations with deficits in motor functioning, making individuals
appear to have visuo-spatial impairments where none exist. Deficits in motor functioning can
contribute to visuo-spatial impairments including “gap errors,” or the inclusion of small spaces
between components of the complex figure task, which in the standard RBANS’ scoring system
are strictly penalized. It is not unreasonable to think that this may contribute, as least in part, to
the low performance of our MS participants on this task. As such, the differences, while not
significant, in visuo-spatial performance between the MS and control group may be due to over
estimation of errors when using the standard RBANS complex figure scoring system, rather than
actual visuo-spatial impairments. A final possibility is that there are no differences in visuospatial function in our MS participants compared to controls, similar to previous research.
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The MS group had slower processing speed compared to normal controls. Our findings
of slow processing speed are consistent with research showing that processing speed deficits are
a core component of the cognitive decline in MS (Bellmann-Strobl et al., 2009). Intact motor
functioning is a prerequisite to adequate performance on many measures associated with
processing speed (D'Orio et al., 2012). Given that we screened and did not find gross motor
impairment in the MS group, it is more likely that the differences in processing speed were due
to true differences, rather than to differential motor functioning.
On measures of executive functioning, our MS participants exhibited deficits in
phonemically constrained word generativity, motor sequencing and planning, perseverative
responding, and maintenance of cognitive set. The finding of impaired executive function in
individuals with MS has been previously reported. For example, Arnett, et al., (1997) found
significant planning deficits on a tower task and Beatty and Monson (1996) found deficits in
concept generativity and increased perseverative responding on a sorting task. Also, both Foong,
et al., (1997) and Henry, et al., (2006) noted deficits in verbal fluency. In addition to working
memory and processing speed deficits, it is likely that deficits are consistent with a subcortical
pattern of cognitive impairments (Lazeron et al., 2005), which provides support for the idea that
the cognitive deficits observed in MS may represent a type of subcortical dementia.
The neuropsychological findings in this study are consistent with previous research
indicating that the cognitive deficits (i.e., deficits in memory, processing speed, attention, and
executive dysfunction) in individuals with MS are consistent with a subcortical dementia and
likely represent damage to subcortical white matter networks.
MSFC Disability Score and Relationship with RBANS
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An area of interest has been the development and application of repeatable, brief
screening tools that can be used to assess cognitive function in MS. We assessed the relationship
between the MSFC and performance on the RBANS. As predicted, the MSFC score was
associated with the RBANS scores for the combined MS and control group, with lower MSFC
scores correlated with cognitive impairments on the RBANS (see Figure 1). When we assessed
the relationship between the MSFC and RBANS scores for the MS group in isolation, the
findings were similar. There was no relationship between MSFC and RBANS scores for the
control group. This finding is not terribly surprising, as the MSFC was designed to assess the
stereotypical deficits in MS – motor, working memory, and processing speed, rather than normal
functioning. As such, one might expect that the MSFC would be a recapitulation of findings on
cognitive measures in an MS group, but not necessarily in a normal control group where
impairments in motor, working memory, and processing speed difficulties are not expected.
Thus, both the MSFC and the RBANS are able to detect cognitive impairments in multiple
sclerosis, and can be used as quick, yet valid tools to assess cognitive impairment in this
population. There are some benefits of using the RBANS over the MSFC as a cognitive
screening tool that should be noted. For example, the MSFC does not sample as many cognitive
domains as does the RBANS, and as such may not be as sensitive to the heterogeneous deficits
seen in MS. Moreover, the RBANS has an estimated administration time of approximately 30
minutes (Randolph, Tierney, Mohr, & Chase, 1998), which is comparable to the time needed to
administer the MSFC, aproximately15 to 20 minutes (Fischer et al., 2001). One advantage of the
RBANS is that it does not use the PASAT, which is a challenging test that is often frustrating for
participants (Tombaugh, 2006) and can be difficult to administer and score (Rosti, Hämäläinen,
Koivisto, & Hokkanen, 2006).
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Quantitative EEG
Amid growing interest in clinical applications of EEG to understand cognitive
functioning in neurological participants (Koberda, Moses, Koberda, & Koberda, 2013), to our
knowledge our study is the first to show the feasibility of QEEG techniques in an MS population
in a clinical neurology setting. We used a standardized 10 – 20 electrode placement system
(Jurcak et al., 2007) in conjunction with standardized clinical measures of cognition that are
sensitive to the deficits seen in MS (e.g., PASAT). This is an innovative use of QEEG
techniques in a clinical setting, and meets the requirements set by Gudmundsson et al., (2007)
and Jurcak et al., (2007) for a valid and useful cognitive-neurophysiological protocol, and such
methods could be used as a guide for future researchers and clinicians who want to implement
these techniques in a research or clinical setting.
Peak Frequency
Initial studies of PAF indicated that it might be a marker of general intelligence, but
researchers have since determined that PAF is associated with cognitive preparedness
(Doppelmayr et al., 2002; Klimesch, 2000). An analysis, utilizing a Repeated Measures
ANOVA, comparing the MS and normal control groups’ performance on both trials on the
PASAT and SPT indicated group level differences in performance for load but not task. Post
hoc analysis indicated that this result was primarily due to significant differences between groups
on the PASAT 3 (light trial). It should be noted that these results are in contrast with previous
research, which has consistently shown that faster presentation (heavier load) is associated with
worsening performance (Tombaugh, 2006). Given that the PASAT 3 second trial was
administered first, per standard MSFC protocol, it is likely that the above results represent
practice effects, which may have been ameliorated by a counter balanced design. Utilizing a
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Repeated Measures ANCOVA, with at rest PAF as the covariate, we found that variance in
performance on the PASAT (measure of mental preparedness and processing speed) was
significantly associated with changes in at rest PAF. Faster at rest PAF correlated with better
performance on the PASAT; this was particularly true for the PASAT 3 second trial. These
results are similar to previous research indicating PAF is associated with cognitive preparedness
in that, as indicated above, a practice effect on the PASAT from the first trial (PASAT 3) to the
second trial (PASAT 2) suggests increased cognitive preparedness as a participant acclimates to
the demands of the task. In contrast to the PASAT data, despite clear differences in performance
accuracy and response speed between the MS and control group PAF was not associated with the
Sternberg Paradigm Task, a measure of working memory (Kahana & Loftus, 1999; Sternberg,
1969). Research by Finnigan and Robertson (2011) found working memory was associated with
theta rather than alpha frequencies. Other research indicates that gamma frequencies are
associated with working memory (Howard et al., 2003). Given the above, at rest PAF would not
necessarily be expected to be related to working memory such as measured by the Sternberg
Paradigm Test. Another possibility is that our SPT was not sufficiently optimized to find load
effects. Thus, PAF is associated with cognitive preparedness and processing speed, both of
which are impaired in MS participants, and therefore may be a viable physiological biomarker of
cognitive decline in MS populations.
Spectral Analysis
We assessed regional differences between the MS and control groups’ peak delta (0-4hz),
theta (4-8hz), alpha (8-12hz), and beta (12-30hz) frequencies while engaged in the PASAT and
found no differences at any electrode site (F3, F4, F7, F8, C3, C4, T3, T4, P3, P4, T5, T6, O1,
O2, Fz, Cz, and Pz). We also compared peak frequencies (delta, theta, alpha, and beta) in MS
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participants with intact cognition with MS participants who had cognitive impairments. There
were no significant differences between the “normal” and cognitively impaired MS groups for
any frequency at any electrode site. This is in contrast with previous research which has shown
increased alpha (Facchetti et al., 1994) and faster peak beta frequencies in MS populations
(Vazquez-Marrufo et al., 2008), but comports with other studies that have shown grossly normal
EEG in the majority of MS participants (Feng, 1981). One possible explanation for the
discrepancies between these studies is that the study by Facchetti et al., and Vazquez-Marrufo et
al., consisted of relatively few participants (n = 16 and n = 19, respectively) whereas Feng et al.,
had a larger samples (n = 57), which decreases the likelihood of false positive errors. Thus, one
possible reason that we did not find differences in peak frequencies in our cognitively impaired
versus “non-impaired” MS participants may be our small sample size (n = 9 and n = 17,
respectively), and as such we may not be powered for subgroup analyses. Further studies are
needed to explore this issue.
Coherence
Coherence represents the degree to which diverse neuronal groups are coupled across
space and time, and, as such, is an indicator of functional connectivity in the brain. Research to
date in MS populations is mixed as to whether coherence decreases as a sign of subcortical
impairment or increases, indicating cognitive adaptation. Our MS participants exhibited
reductions in both intra- and inter-hemispheric coherence in the theta, alpha, and beta bands,
with a limited number of electrode pairs in the theta band showing increased coherence. The
electrode pairs that showed reduction in coherence were generally closer together, while the
electrode pairs in the theta band that showed increased coherence were distant, anterior to
posterior electrode pairs. Leocani, et al., (2000) found decreases in coherence in theta and alpha
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bands during at rest EEG. In contrast, increases in theta, alpha, and beta coherence in an MS
population have also been reported (Schoonheim et al., 2013). While we found a limited number
of electrode pairs that showed increased coherence, our data is most similar to that of Leocani et
al., (2000) who found decreased coherence, and in contrast to Schoonheim et al., (2013) who
found primarily increased coherence. One possible explanation for these discordant findings is
that the Leocani et al. study consisted of MS participants that as a group were cognitively
impaired in comparison to the control group, while in the Schoonheim et al. study the MS
participants had normal cognitive functioning compared to controls. While our MS participants’
general cognitive functioning was in the low average range, it was significantly lower than
matched controls, which makes our population more similar to the Leocani et al. population who
had decreased coherence. It may be that when neuronal networks begin breaking down
coherence decreases, and cognitive functioning is subsequently impaired, which would explain
both our and Leocani et al.’s findings of decreased coherence. Alternatively, adaptive responses,
such as cortical recruitment, may initially result in increased coherence, and maintenance of
cognitive abilities, which would explain Schoonheim et al.’s data. Therefore, coherence may be
a biomarker of both adaptive brain processes (i.e., increased coherence) and brain dysfunction
(i.e., decreased coherence) in MS. While our data is intriguing, our population is small and the
differences between groups modest. Further research is needed to determine the role of
coherence in MS populations as well as the neural implications (brain injury, adaptation, or both)
of such. Finally, while our data did suggest a general reduction in coherence in the MS groups
compared to controls, this effect was not drastic. Given that MS is a disease with a
heterogeneous presentation (i.e., variable lesion location and load across individuals and time) it
may be that group level analysis obscures true differences between groups, and a that
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comparison at the level of the individual participant would be more fruitful. More research is
needed to explore this issue further.
Psychological Functioning
Our MS participants reported significant symptoms of both depression and anxiety
compared to controls (Table 2). These findings are similar to studies that have found depression
to be common in multiple sclerosis (Whitlock & Siskind, 1980). Population based studies
indicate a two to three fold increase in incidence rates of depression in MS participants compared
to non-MS participants (Patten, Beck, Williams, Barbui, & Metz, 2003). Depression is
associated with reduced quality of life, greater fatigue, physical dysfunction, and abnormalities
on structural neuroimaging (Benedict et al., 2005; Feinstein et al., 2010; Feinstein et al., 2004;
Ziemssen, 2009). After accounting for the variance explained by group membership, education,
and electrophysiological differences; psychological functioning (depression and anxiety)
predicted an additional, albeit small (~4 percent), portion of the variance in cognitive
performance (see Table 16) in our MS participants. Data is mixed regarding the relationship
between depression and cognitive impairments in MS. For example, Arnett et al., (1999) found
that depression was associated with reduced working memory capacity. In contrast, Lovera et
al., (2006) found that depression was associated with the perception of cognitive deficits, rather
than with cognitive impairments. Our data tend to support those of Arnettt et al., in that
psychological functioning accounted for variability (four percent) in cognitive functioning in our
MS sample. Given that depression and anxiety are common in MS and that depression appears
to account for a portion of the variability of cognitive function in MS, the effects of depression
should be assessed in studies of cognitive functioning in MS.
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Strengths and Limitations
The strengths of this study include the utilization of quantitative EEG, the inclusion of a
well-defined MS group and carefully matched controls, and use of standardized
neuropsychological measures of cognitive and psychological functioning. In addition, our data
provide support that the RBANS can be used to assess cognitive function in MS participants.
Finally, the electrophysiological data suggests that QEEG may be a promising biomarker of
cognitive deficits in MS. There are a few limitations of the current study. First, given the
amount of data that is generated during a standard EEG and the number of comparisons required
when analyzing such data, and our relatively small sample size, there is an increased possibility
of a Type II error, especially for the individual electrode peak frequency analysis. Second, the
MS group was taking more psychoactive medications than the control group, which may alter
EEG activity (Ford, Goethe, & Dekker, 1986). Specifically, benzodiazepines tend to increase
diffuse beta activity, mood stabilizers increase both delta and theta activity, and antipsychotics,
depending on the method of action, can either decrease or increase alpha frequency (Blume,
2006; Fink, 1969). Given our sample size, we were unable to determine the effect that
medications might have had on our analysis, but it is not unlikely that some effect was present.
Both of these limitations may be alleviated with a larger sample size, and as such, the relatively
small sample size is an important limitation of this study.
Conclusion
In conclusion, our MS population exhibited cognitive impairments in attention,
processing speed, working memory, and executive functioning, which is consistent with previous
research in MS populations. These findings are consistent with the description of MS as a subcortical dementia. We showed that a standardized clinical QEEG protocol used in conjunction
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with cognitive measures is feasible, but care needs to be taken to ensure both task and load
fidelity. Our data indicates that at rest peak alpha frequency is associated with cognitive
preparedness and processing speed, a prominent area of deficit in MS. Coherence was generally
reduced during processing speed tasks in MS, which may indicate subcortical dysfunction. The
electrophysiological data suggests that QEEG may be a promising biomarker of cognitive
deficits in MS. Finally, symptoms of depression and anxiety are prevalent in MS, and depression
was associated with cognitive impairments, and, as such, should be accounted for when assessing
cognitive dysfunction in MS populations.
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